Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 726 | 2021 |
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration D Palacios, C Mozzetta, S Consalvi, G Caretti, V Saccone, V Proserpio, ... Cell stem cell 7 (4), 455-469, 2010 | 440 | 2010 |
Histone deacetylation in epigenetics: an attractive target for anticancer therapy A Mai, S Massa, D Rotili, I Cerbara, S Valente, R Pezzi, S Simeoni, ... Medicinal research reviews 25 (3), 261-309, 2005 | 419 | 2005 |
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2 C Binda, S Valente, M Romanenghi, S Pilotto, R Cirilli, A Karytinos, ... Journal of the American Chemical Society 132 (19), 6827-6833, 2010 | 344 | 2010 |
Oxidative stress and epigenetic regulation in ageing and age-related diseases C Cencioni, F Spallotta, F Martelli, S Valente, A Mai, AM Zeiher, ... International journal of molecular sciences 14 (9), 17643-17663, 2013 | 269 | 2013 |
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue A Galmozzi, N Mitro, A Ferrari, E Gers, F Gilardi, C Godio, G Cermenati, ... diabetes 62 (3), 732-742, 2013 | 248 | 2013 |
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors JH Kalin, M Wu, AV Gomez, Y Song, J Das, D Hayward, N Adejola, M Wu, ... Nature communications 9 (1), 53, 2018 | 199 | 2018 |
Study of 1, 4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors A Mai, S Valente, S Meade, V Carafa, M Tardugno, A Nebbioso, ... Journal of medicinal chemistry 52 (17), 5496-5504, 2009 | 179 | 2009 |
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes A Nebbioso, F Manzo, M Miceli, M Conte, L Manente, A Baldi, A De Luca, ... EMBO reports 10 (7), 776-782, 2009 | 174 | 2009 |
Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors A Mai, D Cheng, MT Bedford, S Valente, A Nebbioso, A Perrone, ... Journal of medicinal chemistry 51 (7), 2279-2290, 2008 | 162 | 2008 |
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy R Mazzone, C Zwergel, A Mai, S Valente Clinical epigenetics 9 (1), 59, 2017 | 144 | 2017 |
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities D Rotili, S Tomassi, M Conte, R Benedetti, M Tortorici, G Ciossani, ... Journal of medicinal chemistry 57 (1), 42-55, 2014 | 134 | 2014 |
Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling B Illi, CD Russo, C Colussi, J Rosati, M Pallaoro, F Spallotta, D Rotili, ... Circulation research 102 (1), 51-58, 2008 | 133 | 2008 |
1, 3, 4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells S Valente, D Trisciuoglio, T De Luca, A Nebbioso, D Labella, A Lenoci, ... Journal of medicinal chemistry 57 (14), 6259-6265, 2014 | 132 | 2014 |
Specific activity of class II histone deacetylases in human breast cancer cells V Duong, C Bret, L Altucci, A Mai, C Duraffourd, J Loubersac, ... Molecular Cancer Research 6 (12), 1908-1919, 2008 | 131 | 2008 |
" Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models … A Savarino, A Mai, S Norelli, S El Daker, S Valente, D Rotili, L Altucci, ... Retrovirology 6, 1-10, 2009 | 129 | 2009 |
Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells S Valente, Y Liu, M Schnekenburger, C Zwergel, S Cosconati, C Gros, ... Journal of medicinal chemistry 57 (3), 701-713, 2014 | 125 | 2014 |
Six years (2012–2018) of researches on catalytic ezh2 inhibitors: the boom of the 2‐pyridone compounds R Fioravanti, G Stazi, C Zwergel, S Valente, A Mai The Chemical Record 18 (12), 1818-1832, 2018 | 98 | 2018 |
Aurones: interesting natural and synthetic compounds with emerging biological potential C Zwergel, F Gaascht, S Valente, M Diederich, D Bagrel, G Kirsch Natural product communications 7 (3), 1934578X1200700322, 2012 | 97 | 2012 |
A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair F Spallotta, C Cencioni, S Straino, S Nanni, J Rosati, S Artuso, I Manni, ... Journal of Biological Chemistry 288 (16), 11004-11012, 2013 | 96 | 2013 |